KIT Inhibitor Compositions for Resistant Mutant KIT and PDGFRA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic agents that inhibit KIT, particularly mutant KIT, and target PDGFRA D842V mutations to treat disorders such as systemic mastocytosis, GIST, AML, melanoma, and seminoma, as well as conditions associated with tyrosine kinase inhibitor resistance.
Innovation Solution
Compounds and compositions that modulate the activity of KIT and PDGFR by incorporating specific structural features to inhibit these targets, as depicted in Formula I, which can be administered to treat or prevent conditions like mastocytosis and mast cell diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents (tyrosine kinase inhibitors like imatinib and sunitinib) are used to treat KIT mutation-related disorders, then some therapeutic effect is achieved, but resistance develops and effectiveness is lost in refractory cases
Solution Approach 1:
The patent employs parameter changes by developing compounds with modified chemical structures (Formula I with specific substituent patterns) that alter the binding characteristics to KIT mutants. The structural parameters including ring systems (Ring A, Ring B), substituent positions (X, Y, Z), and linkage types (L) are optimized to achieve effective inhibition of mutant KIT while overcoming resistance mechanisms that developed against previous generation inhibitors.
2Adaptability or versatility
If broad-spectrum KIT inhibition is pursued to cover multiple mutations, then coverage is improved, but selectivity and potency against specific mutants like D842V may be compromised
Solution Approach 1:
The patent applies universality by designing compounds with structural features that enable broad-spectrum activity against multiple KIT mutations including exon 9, 11, 13, 17, and 18 mutants. The core structure with variable Ring A, Ring B, and substituent patterns allows the compound to accommodate different mutation types while maintaining inhibitory activity, achieving multi-functional coverage of diverse mutant forms.
Solution Approach 2:
The patent applies local quality by incorporating specific substituent patterns at defined positions (X, Y, Z with particular groups) that enhance binding to specific mutant conformations. The localized structural modifications at key positions provide enhanced affinity and selectivity for particular mutation types while the overall framework maintains broad coverage capability.
3Adaptability or versatility
If new compound structures are developed to overcome resistance, then therapeutic options are expanded, but complexity of the chemical structure increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: Ring A with specific substituents, Ring B with defined groups, connecting linkages (L), and terminal groups (X, Y, Z). This modular architecture allows systematic optimization of each segment for resistance overcoming while maintaining overall structural coherence and facilitating medicinal chemistry development.
Data Source
AI summary
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.